Fresenius Medical will acquire all of NxStage’s outstanding shares valued a $30 per share, or about $2 billion.
NxStage’s board approved the transaction. The deal is subject to approval from NxStage stockholders, regulatory approvals and additional closing conditions.
Fresenius projects the transaction will close in 2018.
More articles on transactions and valuation:
Piedmont Healthcare opens 27 retail clinics in Atlanta Walgreens stores
Baylor Scott & White now co-owner of Texas Spine & Joint Hospital
University of Chicago Medicine partners with Community Hospital of Indiana to treat high-risk pregnancies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
